ArticleClinical pharmacology and therapeutics2015
Systems pharmacology augments drug safety surveillance.
Article in Clinical pharmacology and therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Glutathione in Skin Aging and Tissue Regeneration: A Systematic Review of Molecular Mechanisms, Redox Modulation, and Biomedical Implications.Molecules (Basel, Switzerland) · 2026Pooled it
- Computational Advances in Drug Safety: Systematic and Mapping Review of Knowledge Engineering Based Approaches.Frontiers in pharmacology · 2019Pooled it
- Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and computational analyses.PloS one · 2017Pooled it
- Integrating in-silico and experimental validation approaches to unveil the therapeutic mechanism of naringenin against breast cancer.Scientific reports · 2025Article
- Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database.Drugs - real world outcomes · 2022Article
- Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis.British journal of clinical pharmacology · 2022Article
- No population left behind: Improving paediatric drug safety using informatics and systems biology.British journal of clinical pharmacology · 2022Review
- Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug-gene Interaction Network.Frontiers in pharmacology · 2021Article
- Using Machine Learning to Identify Adverse Drug Effects Posing Increased Risk to Women.Patterns (New York, N.Y.) · 2020Article
- A framework for identification of on- and off-target transcriptional responses to drug treatment.Scientific reports · 2019Article
- PathFXweb: a web application for identifying drug safety and efficacy phenotypes.Bioinformatics (Oxford, England) · 2019Article
- Artificial Intelligence for Drug Toxicity and Safety.Trends in pharmacological sciences · 2019Review
- Adverse Event Circumstances and the Case of Drug Interactions.Healthcare (Basel, Switzerland) · 2019Article
- Detecting Potential Adverse Drug Reactions Using a Deep Neural Network Model.Journal of medical Internet research · 2019Article
- PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development.PLoS computational biology · 2018Article
- Identifying signals of interest when screening for drug-outcome associations in health care data.British journal of clinical pharmacology · 2018Article
- Hypothesis-free screening of large administrative databases for unsuspected drug-outcome associations.European journal of epidemiology · 2018Article
- The Next Generation of Drug Safety Science: Coupling Detection, Corroboration, and Validation to Discover Novel Drug Effects and Drug-Drug Interactions.Clinical pharmacology and therapeutics · 2018Article
- A Simple Representation of Three-Dimensional Molecular Structure.Journal of medicinal chemistry · 2017Article
- PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability.Journal of the American Medical Informatics Association : JAMIA · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Small molecule drugs are the foundation of modern medical practice, yet their use is limited by the onset of unexpected and severe adverse events (AEs). Regulatory agencies rely on postmarketing surveillance to monitor safety once drugs are approved for clinical use. Despite advances in pharmacovigilance methods that address issues of confounding bias, clinical data of AEs are inherently noisy. Systems pharmacology-the integration of systems biology and chemical genomics-can illuminate drug mechanisms of action. We hypothesize that these data can improve drug safety surveillance by highlighting drugs with a mechanistic connection to the target phenotype (enriching true positives) and filtering those that do not (depleting false positives). We present an algorithm, the modular assembly of drug safety subnetworks (MADSS), to combine systems pharmacology and pharmacovigilance data and significantly improve drug safety monitoring for four clinically relevant adverse drug reactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.